Background The mode of action of clozapine, an atypical antipsychotic approved for treating schizophrenia (SZ) and used for bipolar disorder (BD) mania, remains unclear. We tested for overlap with the actions of the mood stabilizers, lithium, carbamazepine and valproate, which downregulate arachidonic acid (AA) cascade markers in rat brain and upregulate BDNF. AA cascade markers are upregulated in BD and SZ postmortem BD brain in association with neuroinflammation and synaptic loss, while BDNF is decreased. Methods Rats were injected intraperitoneally with a therapeutically relevant dose of clozapine (10 mg/kg/day) or with saline for 30 days, and AA cascade and synaptic markers and BDNF were measured in the brain. Results Compared with saline-injected rats, chronic clozapine increased brain activity, mRNA and protein levels of docosahexaenoic acid (DHA)-selective calcium-independent phospholipase A 2 type VIA (iPLA 2 ), mRNA and protein levels of BDNF and of the postsynaptic marker, drebrin, while decreasing cyclooxygenase (COX) activity and concentration of prostaglandin E 2 (PGE 2 ), a proinflammatory AA metabolite.
Introduction
Atypical antipsychotics are used widely in the treatment of bipolar disorder (BD) mania as well as schizophrenia (SZ). One of them, clozapine, was approved by the Food and Drug Administration (FDA) for treatment-resistant SZ and was the first atypical antipsychotic to be studied in the treatment of acute bipolar mania (Banov et al. 1994; McElroy et al. 1991) . Open-label trials also suggest that clozapine is effective in BD patients who do not respond to lithium or valproate (Calabrese et al. 1996; Green et al. 2000) . Several mechanisms have been proposed for its efficacy in bipolar mania, but exact mechanisms are not agreed on.
Lithium, valproate and carbamazepine are approved by the FDA as mood stabilizers for treating bipolar mania. Each of these agents, when given chronically to rats to produce a therapeutically relevant plasma concentration, downregulates parts of the brain arachidonic acid (AA; 20:4n−6) cascade including AA turnover in brain phospholipids (all three drugs), AA-selective calcium-dependent phospholipase A 2 (cPLA 2 ) (lithium and carbamazepine), cyclooxygenase (COX)-1 (valproate), COX-2 (all three drugs) and prostaglandin E 2 (PGE 2 ) (all three drugs) (Rao et al. 2007a Rapoport et al. 2009; Rintala et al. 1999) . They also dampen elevations of AA cascade markers induced by neuroinflammation and excitotoxicity (Basselin et al. 2006 (Basselin et al. , 2007a . Of relevance, AA cascade markers are upregulated in the postmortem BD and SZ brain in association with neuroinflammation, excitotoxicity and apoptosis Rao et al. 2010; Rao et al., unpublished observations) .
AA is an n−6 polyunsaturated fatty acid (PUFA) found predominantly in the stereospecifically numbered (sn)-2 position of brain membrane phospholipids together with docosahexaenoic acid (DHA, , and it is released preferentially from this position by cPLA 2 . Most of the released AA is recycled to phospholipid, but a portion is metabolized to bioactive eicosanoids including PGE 2 and thromboxane B 2 (TXB 2 ) by COX-1 or COX-2, or to leukotriene B 4 (LTB 4 ) by lipoxygenases (LOXs). AA and its metabolites modulate signal transduction, gene transcription, neuronal activity, apoptosis and neuroinflammation (Kam and See 2000; Leslie and Watkins 1985) .
At therapeutic doses, clozapine displays an antagonistic effect towards dopamine D 2 receptors, while showing lower D 2 receptor occupancy than other antipsychotics (Farde et al. 1989; Farde et al. 1992b; Kapur et al. 1999; Seeman and Tallerico 1999) . D 2 receptor-mediated signaling potentiates AA release via cPLA 2 through a G-protein coupled mechanism (Bhattacharjee et al. 2008 (Bhattacharjee et al. , 2007 Vial and Piomelli 1995) , and chronic lithium and carbamazepine attenuate D 2 -like receptor-initiated signaling via AA in unanesthetized rats (Basselin et al. 2005 (Basselin et al. , 2008 .
Reduced synaptic connectivity and decreased serum levels of brain-derived neurotrophic factor (BDNF) have been reported in SZ patients (Eastwood et al. 1995; Grillo et al. 2007) , and a recent study showed decreased synaptic markers (presynaptic synaptophysin and postsynaptic drebrin) and BDNF in postmortem brain of BD and SZ patients . Mood stabilizers upregulate BDNF and antiapoptotic marker expression in rat brain, which may account for their neuroprotective action (Chang et al. 2009 ). Similarly, clozapine was reported to promote neurogenesis in the adult rat hippocampus (Halim et al. 2004) .
Based on these observations, we hypothesized that chronic administration of clozapine to rats would downregulate brain AA cascade markers and upregulate BDNF and synaptic integrity. To test this, we examined expression of AA and DHA cascade markers and of synaptic markers and BDNF in brains of rats treated chronically with clozapine. Our results suggest mechanisms of action of clozapine in involving the AA cascade and neuroprotection, which overlap with suggested mechanisms of mood stabilizers ).
Materials and methods

Animals
This study was conducted following the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals (Publication no. 80-23) and was approved by the Animal Care and Use Committee of the National Institute of Child Health and Human Development. Male CDF-344 rats, weighing 180-190 g (Charles River Laboratories, Wilmington, MA), were acclimatized for 1 week in an animal facility with controlled temperature, humidity and light cycle, ad libitum access to food (NIH-31) and water. The NIH diet that was fed the rats was very low in AA but high in DHA. It contained 47.9% LA, 0.02% AA, 5.1% α-LNA and 2.3% DHA (as percent total fatty acid) (DeMar et al. 2006) . Rats were assigned randomly to a chronic clozapine treatment or control (saline) group. Chronic clozapine-treated rats received 10 mg/ kg/day i.p. clozapine dissolved in saline (pH 6.0) once daily for 30 days, while controls received the same volume of saline once daily i.p., also for 30 days. The dose of clozapine was chosen on the basis of D 2 receptor occupancies in the rat brain as determined by Schotte et al. (Farde and Nordstrom 1992a; Farde et al. 1992b; Schotte et al. 1993) . One pharmacokinetic study indicated that serum clozapine concentration after i.p. injection in the rat averages 87 nmol/l per mg/ kg dose, brain concentration is 24-fold higher and half-life elimination time from the brain is 1.5 h (Baldessarini et al. 1993) . Thus, the peak brain clozapine concentration after injection approximated 87×10×24020.9 μmol/kg.
On the last day of dosing, a rat was injected i.p. with its appropriate treatment. For molecular analysis, 3 h after the last injection, the rat was anesthetized with CO 2 and decapitated. The brain was rapidly frozen in 2-methylbutane at −50°C and then stored at −80°C until use. For measuring PGE 2 , TXB 2 and LTB 4 , the rat was lightly anesthetized with sodium pentobarbital (50 mg/kg; Abbott Laboratories, Chicago, IL, USA) and subjected to head-focused microwave irradiation to inactivate enzymes and stop brain metabolism (5.5 kW, 4.8 s; Cober Electronics, Stamford, CT, USA) (DeGeorge et al. 1989; Lee et al. 2008 ).
Preparation of cytoplasmic and membrane extracts
Cytoplasmic and membrane extracts for Western blot analysis were prepared using a compartmental protein extraction kit according to the manufacturer's instructions (Millipore, Temecula, CA, USA). Protein concentrations of cytoplasmic and membrane extracts were determined using Bio-Rad Protein Reagent (Bio-Rad, Hercules, CA, USA).
Western blot analysis
Proteins from cytoplasmic (50 μg) and membrane (50 μg) extracts were separated on 4-20% SDS-polyacrylamide gels (PAGE) (Bio-Rad). Following SDS-PAGE, the proteins were electrophoretically transferred to a nitrocellulose membrane. Protein blots were incubated overnight at 4°C in Trisbuffered saline (TBS), containing 5% nonfat dried milk and 0.1% Tween-20, with specific primary antibodies (1:1,000 dilution) for the group IVA cPLA 2 , group IIA secretory sPLA 2 , group VIA calcium-independent iPLA 2 , COX-1, 5-, 12-and 15-LOX (1:1,000) (Santa Cruz Biotech, Santa Cruz, CA), drebrin, synaptophysin, COX-2 (1:1,000) (Cell Signaling, Beverly, MA) and β-actin (Sigma-Aldrich, St. Louis, MO). Protein blots were incubated with appropriate HRP-conjugated secondary antibodies (Cell Signaling) and visualized using a chemiluminescence reaction (Amersham, Piscataway, NJ) on X-ray film (XAR-5, Kodak, Rochester, NY). Optical densities of immunoblot bands were measured using Alpha Innotech Software (Alpha Innotech, San Leandro, CA) and were normalized to β-actin to correct for unequal loading. All experiments were carried out twice with eight independent samples per group. Values were expressed as percent of control.
BDNF protein BDNF protein levels (picomole per milligram of protein) were measured in brain cytosolic extracts using an ELISA kit according to the manufacturer's instructions (Millipore, Temecula, CA, USA).
Total RNA isolation and real-time RT-PCR Total RNA was prepared from brain using an RNeasy Lipid Tissue Kit (Qiagen, Valencia, CA). cDNA was prepared from total RNA using a high-capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA). mRNA levels were measured by real-time quantitative RT-PCR using the ABI PRISM 7000 sequence detection system (Applied Biosystems). For specific primers and probes for target genes, TaqMan® gene expression assays were purchased from Applied Biosystems, which consisted of a 20× mix of unlabeled PCR primers and Taqman minor groove binder (MGB) probe (FAM dye-labeled). The fold change in gene expression was determined using the ΔΔC T method (Livak and Schmittgen 2001) . Data are expressed as the relative level of the target genes in the chronic clozapineadministered animals normalized to the endogenous control (β-globulin) and relative to the control rats (saline injected) (calibrator), as described previously (Bazinet et al. 2005; Ghelardoni et al. 2004) . All experiments were carried out twice in duplicate with eight independent samples per group. COX activity COX activity was measured in brain cytosolic extracts using a COX activity assay kit according to the manufacturer's instructions (Cayman Chemical, Ann Arbor, MI, USA). Values are expressed as percent of control. PGE 2 , TXB 2 and LTB 4 concentrations PGE 2 , TXB 2 and LTB 4 were extracted using the method of Radin (Radin 1981) . A portion of the extract was dried under nitrogen and assayed for PGE 2 , TXB 2 and LTB 4 using a polyclonal enzyme-linked immunosorbent assay according to manufacturer's instructions (Oxford Biomedical Research, Oxford, MI, USA).
Phospholipase A 2 activities We used a previously described radioactivity method to analyze cPLA 2 and iPLA 2 activities (Cole et al. 2005; Lucas and Dennis 2005; Yang et al. 1999) . A commercial kit (Cayman, Ann Arbor, MI, USA) was used to determine sPLA 2 activity.
Sample preparation
Brain tissue was homogenized with 3 vol. of homogenization buffer (10 mM HEPES, pH 7.5, containing 1 mM EDTA, 0.34 μM sucrose and protease inhibitor cocktail (Roche, Indianapolis, IN)), using a glass homogenizer. The homogenized sample was centrifuged at 100,000g for 1 h at 4°C, and the supernatant was for analysis of PLA 2 enzyme activity Supernatants were kept at −80°C until further use.
Enzyme assay with radioisotope method
To measure cPLA 2 activity, the cytosolic fraction (0.3 mg protein in one assay) was mixed with 100 mM HEPES, pH 7.5 containing 80 μM Ca 2+ , 2 mM dithiothreitol, 0.1 mg/ ml fatty acid-free bovine serum albumin in 450 μl. Fifty microliters of substrate mixture contained 100 μM 1-palmitoyl-2-arachidonoyl-sn-glycerol-3-phosphorylcholine, and phosphatidylinositol 4,5-bisphosphate (97:3) (containing approximately 100,000 dpm of 1-palmitoyl-2-[1-
14 C] arachidonoyl-sn-glycerol-3-phosphorylcholine in one assay) in 400 μM Triton X-100 was added to start the enzymatic reaction. To measure iPLA 2 activity, the cytosolic fraction (0.3 mg protein in one assay) was mixed with 100 mM HEPES, pH 7.5, 5 mM EDTA, 2 mM dithiothreitol and 1 mM ATP in 450 μl. A 50-μl substrate mixture of 100 μM 1-palmitoyl-2-palmitoyl-sn-glycerol-3-phosphorylcholine (containing approximately 100,000 dpm of 1-palmitoyl-2-[1-
14 C] palmitoyl-sn-glycerol-3-phosphorylcholine) in 400 μM Triton X-100 was added to start the enzyme reaction.
Substrate preparation for radioisotope method
The substrates for the iPLA 2 and cPLA 2 activity analyses were prepared fresh daily. Appropriate amounts of cold and radiolabeled phospholipids were added to an appropriate amount of triton X-100, and the mixture was dried with nitrogen gas. Water was added to the residues to give a 10× lipid mixture (1 mM phospholipid, 1,000,000 dpm and 4 mM Triton X-100), which was mixed vigorously.
Enzyme assay
The cytosolic fraction (0.3 mg in one assay) was mixed in 450 μl assay mixture, and 50 μl substrate mixture was added to start the enzyme reaction. The reaction mixture was incubated for 30 min at 40°C and then the reaction was stopped by adding 2.5 ml of Dole reagent (2-propanol, heptane: 0.5 M H 2 SO 4 , 400:100:20, vol/vol/vol). One and a half milliliters of heptane and 1.5 ml H 2 O were added to the mixture, followed by vortexing and centrifugation. The upper phase (about 2 ml) was transferred to a tube, and 200 mg of silicic acid (200-400 mesh) was added, followed by vortexing and centrifugation. The supernatant (1.5 ml) was transferred to a scintillation vial, and scintillation cocktail was added (Ready Safe™ plus 1% glacial acetic acid). Radioactivity of released unesterified fatty acid from substrate was counted as described above. iPLA 2 and cPLA 2 activities were expressed as the release rate of fatty acid from phospholipid.
Statistical analysis
Data are presented as mean ± SD (n08 for each group). An unpaired Student'st test was used to compare means, taking p<0.05 as the cutoff for statistical significance.
Results
Effects of chronic clozapine administration on body and brain weight Mean body weight was 225.4±4.0 g and 228.9±4.5 g in the control and clozapine groups, respectively (p00.12). Chronic clozapine administration reduced body weight significantly (276.3 ± 9.6 g and 251.5 ± 13.4 g in the control and clozapine groups, respectively (p < 0.001)) but did not change brain weight (1.9±0.1 g and 1.9±0.1 g, respectively (p00.40)). No difference was seen in the AA and DHA concentrations in brain phospholipids between control and clozapine groups (unpublished data).
Effects of chronic clozapine administration on activity and expression of PLA 2 enzymes Brain iPLA 2 activity was increased significantly (p<0.05) in rats given chronic clozapine compared with saline (Fig. 1c) . The increase was accompanied by a significant increase in iPLA 2 VIA mRNA (p<0.01) and protein (p<0.05) (Fig. 1a  and b ). Brain cPLA 2 activity (Fig. 1f) , mRNA (Fig. 1d) and protein ( Fig. 1e) were not changed significantly by clozapine, nor were brain sPLA 2 activity, protein or mRNA (Fig. 1g-i) .
Effects of chronic clozapine administration on activity and expression levels of COX-1 and COX-2 Brain COX-1 mRNA was increased significantly (p<0.01) (Fig. 2a ) in rats treated with clozapine compared with controls but COX-1 protein was unchanged (Fig. 2c) . Chronic clozapine did not alter COX-2 mRNA or protein levels significantly ( Fig. 2b and d) but decreased COX-1 activity and total COX activity (Fig. 3) .
Effects of chronic clozapine administration on mRNA and protein levels of 5-LOX, 12-LOX and 15-LOX Brain 5-and 15-LOX mRNA levels were increased significantly (p<0.001) in the brain of rats treated with clozapine compared to the control group (Fig. 4a and c) , while 5-and 15-LOX protein levels were unchanged ( Fig. 4d and f) . mRNA and 12-LOX protein were not significantly different between the two groups ( Fig. 4b and e) .
Effects of chronic clozapine on PGE 2 , TXB 2 and LTB 4 The brain PGE 2 concentration was decreased significantly by chronic clozapine, with no significant change in LTB 4 concentration ( Fig. 5a and c) . The TXB 2 concentration was increased significantly (Fig. 5b) .
Effects of chronic clozapine on mRNA and protein levels of BDNF Compared with control brain, chronic clozapine significantly increased mean protein (p<0.001) and mRNA (p<0.01) levels of BDNF (Fig. 6 ). Fig. 1 mRNA, protein and activity levels of PLA 2 enzymes in brains of rats treated with clozapine or saline (control). mRNA, protein l and activity levels of iPLA 2 (a-c), cPLA 2 (d-f) and sPLA 2 (g-i). mRNA data are expressed as the relative level of PLA 2 normalized to the endogenous control (β-globulin) using the ΔΔC T method. Protein levels are the ratios of optical density of PLA 2 to β-actin, expressed as percent of control. Values are mean ± SD (n08 for both groups). Asterisk indicates p<0.05, two asterisks indicate p<0.01. C control, CZ clozapine Effects of chronic clozapine on mRNA and protein levels of drebrin and synaptophysin Compared with the control brain, mean mRNA and protein levels of drebrin were increased significantly by chronic clozapine administration ( Fig. 7b and d) (p < 0.05), while the synaptophysin levels were unchanged ( Fig. 7a and c) .
Discussion
Chronically administered clozapine decreased COX-1 and total COX activities and the concentration of the proinflammatory AA metabolite PGE 2 (Bazan 2007) in the brain, while it increased activity and expression (mRNA and protein) of iPLA 2 and mRNA levels of 5-and 15-LOX. Activity and expression levels of cPLA 2 and sPLA 2 were not Values are mean ± SD (n08 for both groups). Two asterisks indicate p <0.01. C control, CZ clozapine significantly affected. Expression levels of BDNF and postsynaptic drebrin were significantly increased by clozapine, but expression of presynaptic synaptophysin was unchanged. Clozapine's effects on COX activity, PGE 2 and BDNF overlap with reported effects of mood stabilizers (lithium, valproate and carbamazepine) in the rat brain (Chang et al. 2009; Rao et al. 2007a Rao et al. , 2008 . Given that AA cascade markers are upregulated and that BDNF and drebrin are reduced in the postmortem BD brain, in association with neuroinflammation and excitotoxicity Rao et al. 2010) , these results suggest common antiinflammatory and neuroprotective mechanisms for the antimanic efficacy of clozapine and mood stabilizers (Basselin et al. 2007b; Peng et al. 2005; Rapoport et al. 2009 ). With regard to our negative finding for synaptophysin, other studies have shown that synaptophysin protein was not affected by 2 weeks but was increased by 9 weeks of clozapine administration (Bragina et al. 2006; Eastwood et al. 2001a; Eastwood and Harrison 2001b) .
15-LOX (75 kDa)
β-actin (45 kDa) One difference between clozapine and mood stabilizer effects in rat brain, however, is the upregulation of transcription and activity of iPLA 2 type VIA caused by clozapine, which is not produced by mood stabilizers ). iPLA 2 selectively releases DHA from the sn-2 position of membrane phospholipid (Garcia and Kim 1997; Ramadan et al. 2010; Six and Dennis 2000; Strokin et al. 2004) , and its activity in rat brain correlates with brain DHA concentration and DHA turnover and metabolism (Igarashi et al. 2011; Rao et al. 2007b) . As DHA and its metabolites have antiinflammatory properties (Bazan 2007; Serhan 2006) and neuroinflammation characterizes the BD brain , increased iPLA 2 expression, which also occurs following chronic administration of olanzapine to rats (Cheon et al. 2011) , provides an additional possible mechanism for clozapine's efficacy in BD. A therapeutic effect of upregulated DHA metabolism is consistent with reported positive effects of dietary n−3 PUFA supplementation in BD patients (Freeman et al. 2006; Montgomery and Richardson 2008) .
Clozapine can produce unwanted side effects in patients, particularly weight gain and diabetes associated with glucose intolerance and insulin resistance (Henderson 2001) . iPLA 2 can modulate glucose metabolism and energy balance, since inhibition of iPLA 2 in beta cells reduces insulin levels while its overexpression amplifies insulin secretion (Ramanadham et al. 2003; Song et al. 2005; Wilkins and Barbour 2008) . The glucose metabolic effects of clozapine may be associated with upregulated iPLA 2 in these cells, but this has to be tested. Unlike its reported obesity effect in humans (Henderson 2001) , clozapine-treated rats had lesser body weight (10%) compared with untreated rats in this study. Our finding is in line with similar findings in male mice and rats treated with clozapine (Baptista et al. 1993;  BDNF protein (ELISA) BDNF mRNA A B . mRNA data are expressed as relative levels of synaptophysin or drebrin normalized to the endogenous control (β-globulin) using the ΔΔC T method. The protein level is the ratio of optical density of synaptophysin or drebrin to β-actin, expressed as percent of control. Values are mean ± SD (n08 for both groups). Asterisk indicates p< 0.05. C control, CZ clozapine Cheng et al. 2005; Rolsten et al. 1979 ) and in female rats given different doses of clozapine (Shobo et al. 2011 ). Clozapine's complex metabolic and weight effects in rodents have been related to changes in feeding efficiency, adiposity, locomotor activity and satiety signaling (Cooper et al. 2008; Shobo et al. 2011) .
In the brain, cPLA 2 is coupled by a G-protein mechanism to the postsynaptic dopamine D 2 receptor, and clozapine, like lithium and carbamazepine, can block AA signaling involving the D 2 receptor (Basselin et al. 2008; Bhattacharjee et al. 2008; Kapur et al. 1999; Ong et al. 1999) . We expected to find cPLA 2 downregulated following clozapine, but we did not, although we did find reduced downstream effects on COX activity and PGE 2 concentration and on AA consumption by brain, and the concentration of unesterified plasma AA (Modi et al., unpublished observation) . Clozapine also decreases brain AA metabolism in mice lacking apolipoprotein D but not in wildtype controls (Thomas and Yao 2007) . Clozapine may not affect cPLA 2 under basal conditions but may prevent its upregulation with loss of function of a gene or with neuroinflammation. Thus, it may be worthwhile to investigate effects of clozapine in animal models of neuroinflammation, which have upregulated AA cascade markers including COX-2, cPLA 2 , brain AA consumption and PGE 2 concentration (Basselin et al. 2007b; Lee et al. 2008; Rao et al. 2007b) .
Protein levels of 5-, 12-, and 15-LOX were unchanged following chronic clozapine, but mRNA levels of 5-and 15-LOX were increased significantly. Since COX and LOX metabolize AA, the LOX mRNA changes may be compensatory responses to reduced COX activity. Similarly, increased TXB 2 could be a compensatory response associated with the reduced PGE 2 .
Olanzapine, another atypical antipsychotic approved for treating SZ and BD, has similar effects to clozapine in rat brain. Like clozapine, olanzapine decreases brain COX activity and PGE 2 concentration, while increasing iPLA 2 mRNA and reducing brain AA consumption (Cheon et al 2011) . Thus, downregulation of COX-mediated AA metabolism might be a shared mechanism of atypical antipsychotics related to their clinical efficacy.
Reduced serum BDNF level in SZ patients and decreased synaptic markers (synaptophysin and drebrin) and BDNF in the postmortem BD or SZ brain have been reported (Grillo et al. 2007; Kim et al. 2011; Rao et al., unpublished) . Chronic administration of mood stabilizers increases BDNF in rat brain (Chang et al. 2009 ), as does chronic clozapine. Clozapine also increased expression of drebrin, which is found in postsynaptic excitatory dendritic spines (Shirao 1995) , but did not change the presynaptic synaptophysin level. The drebrin effect may be associated with upregulated DHA metabolism and increased iPLA 2 activity, since dietary DHA supplementation increased brain drebrin levels in mouse models of Alzheimer's disease (Calon et al. 2004; Perez et al. 2010) . Clozapine also increases postsynaptic microtubule-associated protein (MAP)-2 and promotes neurogenesis in rat brain (Halim et al. 2004; Law et al. 2004) . Overall, the changes in BDNF and postsynaptic markers suggest that clozapine provides neuroprotection in BD and SZ.
In an ongoing study, we are measuring fatty acid content using lipid analytical techniques of body compartments in clozapine-treated and control rats (Modi et al., unpublished) . Preliminary results indicate that there is no difference in AA or DHA concentration in brain phospholipids between clozapine treatment and control rats, while concentrations of both fatty acids are reduced in plasma of treated animals, likely secondary to an effect on liver and other aspect of body metabolism (Cooper et al. 2008; Shobo et al. 2011 ).
In conclusion, chronic clozapine caused a number of molecular changes in the rat brain, consistent with downregulation of some aspects of AA metabolism (COX activity and PGE 2 concentration) and with upregulation of DHA metabolism (activity, mRNA and protein levels of DHAselective iPLA 2 ), as well as increased mRNA and protein levels of BDNF and of the postsynaptic marker, drebrin, suggesting neuroprotection. Some of these changes overlap with changes produced by mood stabilizers in rat brain (e.g., reduced COX activity and PGE 2 concentration and reduced brain BDNF) but some do not (lithium and carbamazepine reduced expression and activity of AA-selective cPLA 2 and the mood stabilizers did not change expression of iPLA 2 or DHA turnover in phospholipids). Since clozapine reduced plasma unesterified AA and DHA concentrations in rats (Modi et al., unpublished observations), some brain effects that we report here may be secondary to changes in plasma availability of AA and DHA. This interpretation is supported by evidence that chronic administration of olanzapine also decreased plasma unesterified AA concentration, brain COX activity and PGE 2 concentration. Incorporation rates and turnover of AA within brain phospholipids were also decreased by olanzapine (Cheon et al. 2011 ).
This study shows that some effects of clozapine overlap with those of mood stabilizers in the rat brain, arguing for certain common mechanisms of their therapeutic action. Clozapine and other atypical antipsychotics are thought to act in patients by blocking D 2 receptor activation and downstream signaling (Kapur et al. 1999 ). Lithium and carbamazepine also have D 2 receptor antagonist properties involving AA signaling (Basselin et al. 2005 (Basselin et al. , 2008 . Mood stabilizers like clozapine upregulate BDNF expression in rat brain (Chang et al. 2009 ). Clozapine appears to be additionally neuroprotective by increasing drebrin and BDNF expression. These animal studies showing overlapping actions are relevant because the postmortem BD or SZ brain displays reduced expression of drebrin, BDNF and the dopamine reuptake transporter and increased expression of AA cascade markers Rao et al. 2010 Rao et al. , 2012 Rapoport et al. 2009 ). Since common polygenic variation contributes to risk for SZ and BD (Purcell et al. 2009 ), targeting the AA cascade in animal models may be useful for developing and screening new drugs for SZ and BD.
